FutureMeds Named as One of Britain’s Fastest-growing Private Businesses On The Sunday Times 100
- FutureMeds
- 3 hours ago
- 4 min read
FutureMeds has been ranked #44 on The Sunday Times 100 list of Britain’s fastest-growing private companies with 96.73% annual growth over three years.
Founded in late 2019 by Chief Executive Dr. Radoslaw Janiak, Chief Financial Officer Marcin Gondek, and Chairman Paul Chambers, FutureMeds was created to remove long-standing bottlenecks in the clinical research ecosystem. Their goal was to build a purpose-driven, fully owned, pan-European site network capable of running trials at scale without losing the local touch patients and sponsors need.
“The growing volume of new trials, the rise of biotech sponsors with limited clinical operations experience, and increasingly complex protocols are exposing the limits of traditional trial execution. At FutureMeds, we’ve built a dedicated site network that combines industrial-scale efficiency with decentralised service, allowing us to flex to each trial’s unique needs while keeping patients firmly at the centre. It’s this combination of scale, adaptability, and human focus that enables us to deliver what the industry now demands. Being recognised by The Sunday Times is a proud milestone and our growth is a clear signal we’re on the right path.”
— Dr Radoslaw Janiak, CEO, FutureMeds
The Growth Behind the Ranking
While this ranking celebrates commercial growth, for us, it’s always been about impact. We’ve expanded access to trials, improved start-up timelines, and enabled more diverse populations to participate in research.
Few recent highlights:
Conducted over 200 trials in 2024 across site and decentralised models
Randomised 4,720 patients in 116 studies in 2024
Delivered 1,440+ home visits via our decentralised solution, FutureMeds @home in 2024
Soft-launched an ambulatory oncology program to reduce barriers in cancer trial participation with more than 10 of our sites recruiting patients for this indication or will soon start
Rolled out the Progress P.A.C.T., a company-wide cultural framework focused on Patients, Clients, Partners, and our People
Expansion: in Romania with 2 sites, Lviv in Ukraine, London in the UK and other sites opening soon
Our model also stood up to regulatory scrutiny, with succesful audits from the FDA, Korean MoH, BVMA Germany, and multiple sponsors. We deepened relationships with health systems like the NHS in the UK and Viamed Salud in Spain, and were proud to join industry programmes such as IQVIA Prime Site Network, Medpace’s Flagship Site Program, and Fortrea’s Site Advisory Board.
“We expanded trial accessibility, enhanced feasibility, and upheld quality while scaling our operations across Europe. Our site and DCT capabilities continue to offer sponsors flexible, efficient ways to run trials that meet real-world needs.”
— Iwona Tongbhoyai, Chief Client Solutions Officer
Progress Starts with People
At the heart of FutureMeds’ growth story is something simple but powerful: people.
From principal investigators to clinical coordinators guiding patients through visits, every milestone we’ve reached has been built on human effort, dedication and expertise. Across 7 countries, our site teams show up each day with a shared purpose: to make clinical research more accessible, consistent, and impactful.
In early 2024, we launched the Progress P.A.C.T., our cultural framework and internal compass. It reflects our deep commitment to our Patients, Clients, Partners, and our People and shapes everything from operational decision-making to leadership development.
"Our people are our greatest asset. In 2025, we are prioritising developing talent and enhancing colleague experience. We aim to co-create an environment where growth and collaboration thrive, allowing everyone to contribute meaningfully to the growth of our company and our contribution to medical progress."
— Melanie Manners, Group HR Director
To support that ambition, we made strategic investments in people infrastructure:
Appointed an experienced Group HR Director to the executive team
Rolled out new leadership development programs
Launched initiatives to promote cross-country knowledge sharing
Integrated structured feedback and recognition mechanisms
Built stronger alignment between operations and culture across all functions
And it’s making a difference. Over 80% of colleagues said they would recommend FutureMeds as a great place to work. External partners are noticing, too, commenting that “FutureMeds teams everywhere seem aligned in purpose and approach”, “We started working with them from the start and will continue to do so because they are now one of the elite sites in the programme”, “Staff are well-trained & consistent”.
Looking Forward
“Standing at #44 on the Times 100 list is both a celebration and a challenge. We celebrate being among the companies driving Britain’s economic engine, and we acknowledge the challenge to keep innovating and improving,“ added Dr Radoslaw Janiak, CEO.
“The spotlight is certainly on us. Clients are looking to us for even more capacity, and talented professionals are considering building their careers within FutureMeds.”
“Our plan for the next phase of growth is firmly rooted in the ethos that got us this far: delivering tomorrow's medicines today by accelerating access to research. We are opening sites across Europe, continue strengthening partnerships with national healthcare systems, local hospitals, and extending our decentralised trial capabilities.”
As we reflect on this milestone, one word keeps coming up: gratitude.
We’re grateful to our team, who often go above and beyond. We’re grateful to our clients and partners for entrusting us with their important studies. We’re grateful to the patients and volunteers in our trials, who are the true heroes. Their willingness to participate in research is the reason any of this growth matters at all.
Finally, we thank The Sunday Times 100 for recognising our teams’ work. To be counted among these 100 dynamic businesses is an honour that humbles us.
About The Sunday Times 100
The Sunday Times' fourth annual ranking, published online on Friday 27 June 2025, recognises Britain's 100 fastest-growing private companies, excluding those which sell their own technology.
This year, The Sunday Times 100 excludes companies that sell their own technology, which now feature in the sister table, The Sunday Times 100 Tech, launched in January 2025.
The research for The Sunday Times 100 found that, on average, the top 100 fastest-growing companies have increased their sales by 111% a year over the last three years, to a combined £3.4 billion in sales.
The Sunday Times 100 is sponsored by Barclays Private Bank and supported by S&W, the professional services firm, Oracle NetSuite and Singer Capital Markets.
The Sunday Times 100 Britain’s fastest-growing private businesses is available online at thesundaytimes.com/100 and as a supplement with the print edition of the newspaper on Sunday, 29 June 2025.
Comments